146 related articles for article (PubMed ID: 18925876)
1. Ligation of tumour-produced mucins to CD22 dramatically impairs splenic marginal zone B-cells.
Toda M; Hisano R; Yurugi H; Akita K; Maruyama K; Inoue M; Adachi T; Tsubata T; Nakada H
Biochem J; 2009 Feb; 417(3):673-83. PubMed ID: 18925876
[TBL] [Abstract][Full Text] [Related]
2. Down-modulation of B cell signal transduction by ligation of mucins to CD22.
Toda M; Akita K; Inoue M; Taketani S; Nakada H
Biochem Biophys Res Commun; 2008 Jul; 372(1):45-50. PubMed ID: 18474217
[TBL] [Abstract][Full Text] [Related]
3. Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice.
Sugihara I; Yoshida M; Shigenobu T; Takagi H; Maruyama K; Takeuchi N; Toda M; Inoue M; Nakada H
Cancer Res; 2006 Jun; 66(12):6175-82. PubMed ID: 16778191
[TBL] [Abstract][Full Text] [Related]
4. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
Tedder TF; Poe JC; Haas KM
Adv Immunol; 2005; 88():1-50. PubMed ID: 16227086
[TBL] [Abstract][Full Text] [Related]
5. CD22 serves as a receptor for soluble IgM.
Adachi T; Harumiya S; Takematsu H; Kozutsumi Y; Wabl M; Fujimoto M; Tedder TF
Eur J Immunol; 2012 Jan; 42(1):241-7. PubMed ID: 21956693
[TBL] [Abstract][Full Text] [Related]
6. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).
Fung PY; Longenecker BM
Cancer Res; 1991 Feb; 51(4):1170-6. PubMed ID: 1825477
[TBL] [Abstract][Full Text] [Related]
7. Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding.
Nitschke L; Lajaunias F; Moll T; Ho L; Martinez-Soria E; Kikuchi S; Santiago-Raber ML; Dix C; Parkhouse RM; Izui S
Int Immunol; 2006 Jan; 18(1):59-68. PubMed ID: 16291654
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity.
Mihaylova N; Voynova E; Tchorbanov A; Dolashka-Angelova P; Bayry J; Devreese B; Kaveri S; Vassilev T
Mol Immunol; 2009 Nov; 47(1):123-30. PubMed ID: 19243823
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of marginal zone B-cells in unimmunized mice.
Kishi Y; Tsubata T
J Med Dent Sci; 2009 Mar; 56(1):49-54. PubMed ID: 19697518
[TBL] [Abstract][Full Text] [Related]
10. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms.
Poe JC; Fujimoto Y; Hasegawa M; Haas KM; Miller AS; Sanford IG; Bock CB; Fujimoto M; Tedder TF
Nat Immunol; 2004 Oct; 5(10):1078-87. PubMed ID: 15378059
[TBL] [Abstract][Full Text] [Related]
11. Isolation and partial characterization of an epiglycanin-like glycoprotein from a new non-strain-specific subline of TA3 murine mammary adenocarcinoma.
Codington JF; Cooper AG; Miller DK; Slayter HS; Brown MC; Silber C; Jeanloz RW
J Natl Cancer Inst; 1979 Jul; 63(1):153-61. PubMed ID: 286825
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide.
Bakker TR; Piperi C; Davies EA; Merwe PA
Eur J Immunol; 2002 Jul; 32(7):1924-32. PubMed ID: 12115612
[TBL] [Abstract][Full Text] [Related]
13. Expansion of CD22lo B cells in the spleen of autoimmune-prone flaky skin mice.
Mattsson N; Duzevik EG; Pelsue SC
Cell Immunol; 2005 Apr; 234(2):124-32. PubMed ID: 16054613
[TBL] [Abstract][Full Text] [Related]
14. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin.
Itoh Y; Kamata-Sakurai M; Denda-Nagai K; Nagai S; Tsuiji M; Ishii-Schrade K; Okada K; Goto A; Fukayama M; Irimura T
Glycobiology; 2008 Jan; 18(1):74-83. PubMed ID: 17977904
[TBL] [Abstract][Full Text] [Related]
15. Reduction of marginal zone B cells in CD22-deficient mice.
Samardzic T; Marinkovic D; Danzer CP; Gerlach J; Nitschke L; Wirth T
Eur J Immunol; 2002 Feb; 32(2):561-7. PubMed ID: 11828373
[TBL] [Abstract][Full Text] [Related]
16. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth.
Cooper AG; Codington JF; Miller DK; Brown MC
J Natl Cancer Inst; 1979 Jul; 63(1):163-9. PubMed ID: 221714
[TBL] [Abstract][Full Text] [Related]
17. c-fos overexpression in splenic B cells augments development of marginal zone B cells.
Yamashita K; Sakamoto A; Ohkubo Y; Arima M; Hatano M; Kuroda Y; Tokuhisa T
Mol Immunol; 2005 Mar; 42(5):617-25. PubMed ID: 15607821
[TBL] [Abstract][Full Text] [Related]
18. CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.
Haas KM; Johnson KL; Phipps JP; Do C
J Immunol; 2018 Mar; 200(5):1671-1681. PubMed ID: 29374074
[TBL] [Abstract][Full Text] [Related]
19. B cell activation. II. Receptor cross-linking by thymus-independent and thymus-dependent antigens induces a rapid decrease in the plasma membrane potential of antigen-binding B lymphocytes.
Monroe JG; Cambier JC
J Immunol; 1983 Dec; 131(6):2641-4. PubMed ID: 6196393
[TBL] [Abstract][Full Text] [Related]
20. Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against Streptococcus pneumoniae.
Koppel EA; Litjens M; van den Berg VC; van Kooyk Y; Geijtenbeek TB
Mol Immunol; 2008 May; 45(10):2881-7. PubMed ID: 18343501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
